Imugene Ltd · ASX:IMU
Imugene — Investor Presentation (November 2006)
14 slides from Imugene's investor presentation, November 2006

Slide 1: Imugene Animal Health Biological Products Investor Presentation
IMUGENE Animal Health Biological Products Investor Presentation November 2006 Dr Warwick Lamb Managing Director

Slide 2: A biopharmaceutical company
IMUGENE A biopharmaceutical company • Niche Australian biopharmaceutical company developing and commercialising biological animal health products for the intensive pig and poultry industries worldwide • Adenovirus vectors for vaccine development and productivity enhancement • Residue free and non-ch

Slide 3: Product & Industry Focus
IMUGENE Product & Industry Focus • Proven & patented platform science • Advanced products with market demand & need • Strong product pipeline • Early licensing success • Early regulatory approvals • Small focused team with histories of successful product commercialisation in international animal hea

Slide 4: Competitive Advantages
Competitive Advantages • Large global target markets • Biologicals - shorter regulatory timeframes – US Dept of Agriculture – Not FDA – Quicker to market and revenues than drugs – Longer revenue stream under patent • Strong patent protection in major producing territories

Slide 5: Competitive Advantages
Competitive Advantages • Strong platform for product portfolio • Easy to administer (feed, water or aerosol), • Do not require injection or animal handling • Inexpensive to manufacture • Safe – No cross species infection – Residue free in animal – No genetic modification of animal

Slide 6: Commercial Agreements
COMMERCIAL AGREEMENTS • First product successfully licensed to Merial (Merck and sanofi-aventis jv company - US$2.05 Billion pa sales) – world leading animal health company • Product development agreement signed with Abic (Teva pharmaceuticals – global Top 20 human pharma) to develop a chicken vacci

Slide 7: Poultry Productivity Enhancer
Poultry Productivity Enhancer – Licensed to Merial in Oct 2005 – Trial results show • increased poultry growth up to 15% (antibiotics <4%) • 9% improvement in Feed Conversion Ratio – Completion of two Australian safety trials – Sign-up fees received & milestone payment recently earned – Progressing

Slide 8: Avian Influenza
Avian Influenza – Two vaccine candidates completed • For broilers & layers/breeders – Fully lab tested – High quality trial site secured in US – Poultry trials to commence this quarter – Successful grant funding of $882,000 for product development – International interest

Slide 9: Coccidiosis Vaccine
Coccidiosis Vaccine • Contract to construct vaccine candidates for Teva/Abic • Vaccine candidates completed • Final candidate verification underway • Expect to handover to Teva/Abic for poultry trials in early 2007 • Anticipate licensing FAV for delivery of these vaccines if successful in trials

Slide 10: Pig Vaccines
Pig Vaccines – PRRS vaccine • World’s most important pig disease • Market US$200m-$400m pa • No effective vaccine • Successful pig trials and is being fast-tracked with further US based trials – PAV-Merial – Respiratory disease • Market US$300 M pa • Evaluated by Merial for major markets – Other PAV

Slide 11: Company Progression
Company Progression • Develop poultry and pig product portfolio – Range of PAV & FAV based vaccines – Progress each vaccine candidate • Vaccine candidate construction - Australia • Clinical Trials – US and Europe • Expand international commercial alliances • Flexible commercialisation strategy

Slide 12: Financial Position
Financial Position • Net cash outflow – $137k/mth = under budget • 2007 budget approx $150k/mth • Merial funding development work on Poultry Productivity Enhancer • $2.3m cash as at Sep 06 • $880k Aust Govt grant for Bird Flu – drawn over 2yrs • Financial returns from Merial licence • Contract payme

Slide 13: Corporate
Corporate • Directors & management – Graham Dowland – Chairman – Warwick Lamb – CEO – Roger Steinepreis – Director – Mike Sheppard – Chief Scientific Officer • Shares on issue 130 m (QIC – 5.7%, Board – 13%) • Options on issue – Expiry 31 Dec 06 (25c-30c) 6.2 m – Expiry 31 Jan 07 (50c) 4.5 m – Expir

Slide 14: Key Points
Key Points • Experienced management • Large existing global markets • Potential to expand markets with new products • Multiple commercialisation strategies • Multinational pharmaceutical validation – including Merial • Effective & safe – no residue or genetic modification of animal, • IP secure – pa
Source: Internet Archive copy of imugene.com
More decks from Imugene Ltd
Investor Presentation (July 2026)29 slides · Jul 7, 2026
Investor Presentation (March 2026)31 slides · Mar 11, 2026
Technical Presentation (February 2026)15 slides · February 2026
Shareholder Meeting (November 2025)16 slides · Nov 13, 2025
Shareholder Meeting (August 2025)6 slides · Aug 20, 2025
Investor Presentation (July 2025)37 slides · Jul 16, 2025